Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

3,323

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Diabetes Mellitus
Interventions
DRUG

Alogliptin

Alogliptin tablets.

Trial Locations (114)

Unknown

Birmingham

Peoria

Phoenix

Anaheim

Artesia

Fresno

Los Angeles

Mission Viejo

Northridge

Orange

San Diego

Tustin

Walnut Creek

Colorado Springs

Denver

Norwalk

Washington D.C.

Clearwater

Hollywood

Kissimmee

Longwood

New Port Richie

Ocala

Ocoee

Saint Cloud

Lawrenceville

Honolulu

Idaho Falls

Chicago

Avon

Elkhart

Evansville

Lafayette

Erlanger

Baltimore

Sudbury

Chesterfield

St Louis

Omaha

Berlin

Burlington

Charlotte

Morehead City

Pinehurst

Winston-Salem

Cincinnatti

Dayton

Tulsa

Medford

Lansdale

West Grove

Charleston

Columbia

Simpsonville

Bristol

Cookeville

Milan

Dallas

San Antonio

Temple

Texarkana

Burlington

Buenos Aires

Buenos Aires

Rosario

Buenos Aires

Ciudadd Autonoma de Buenos Aires

Córdoba

Mar del Plata

Fortaleza

Curitiba

Porto Alegre

Mogi das Cruzes

Santos

São Paulo

Santiago

Ostrava

Prague

Sternberk

Zlín

Santo Domingo Oeste

Aschaffenburg

Berlin

Frankfurt

Hamburg

Hanover

Munich

Nuremberg

Schwerin

Wiesbaden

Witten

Guatemala City

Almere Stad

De Bilt

Geleen

Oud-Beijerland

Rotterdam

Zwijndrecht

Bellavista

San Isidro

Ica

Lima

Bytom

Kamieniec Ząbkowicki

Krakow

Lodz

Radom

Łęczyca

Pretoria

Cape Town

Somerset West

Durban

Johannesburg

Parow

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY